Latest Insider Transactions at Adverum Biotechnologies, Inc. (ADVM)

ADVM Quotes by TradingView

This section provides a real-time view of insider transactions for Adverum Biotechnologies, Inc. (ADVM). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Adverum Biotechnologies, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Adverum Biotechnologies, Inc.'s insiders and make more informed investment decisions.

Insider Transaction List

Date Insider Transaction Ownership Type Shares Traded Value / Price
Apr 02 2025
Braden Michael Leonard
BUY
Open market or private purchase
Indirect
15,209 +0.55%
$60,836 $4.04 P/Share
Mar 31 2025
Braden Michael Leonard
BUY
Open market or private purchase
Indirect
19,566 +0.71%
$78,264 $4.38 P/Share
Mar 27 2025
Braden Michael Leonard
SELL
Open market or private purchase
Direct
16,593 -10.48%
$82,965 $5.19 P/Share
Mar 26 2025
Braden Michael Leonard
BUY
Open market or private purchase
Direct
20,407 +14.01%
$102,035 $5.04 P/Share
Mar 20 2025
Braden Michael Leonard
BUY
Open market or private purchase
Indirect
30,600 +1.11%
$153,000 $5.61 P/Share
Mar 19 2025
Braden Michael Leonard
BUY
Open market or private purchase
Indirect
25,000 +0.92%
$100,000 $4.94 P/Share
Mar 18 2025
Braden Michael Leonard
BUY
Open market or private purchase
Indirect
62,341 +1.16%
$249,364 $4.67 P/Share
Feb 28 2025
Braden Michael Leonard
BUY
Open market or private purchase
Indirect
85,068 +3.16%
$340,272 $4.6 P/Share
Feb 27 2025
Braden Michael Leonard
BUY
Open market or private purchase
Indirect
86,802 +3.33%
$347,208 $4.46 P/Share
Feb 26 2025
Braden Michael Leonard
BUY
Open market or private purchase
Indirect
164,886 +6.35%
$659,544 $4.01 P/Share
Feb 25 2025
Laurent Fischer CEO, PRESIDENT AND DIRECTOR
BUY
Grant, award, or other acquisition
Direct
25,000 +20.56%
-
Feb 25 2025
Setareh Seyedkazemi CHIEF DEVELOPMENT OFFICER
BUY
Grant, award, or other acquisition
Direct
8,125 +35.61%
-
Feb 25 2025
Rabia Gurses Ozden Chief Medical Officer
BUY
Grant, award, or other acquisition
Direct
8,125 +50.0%
-
Feb 25 2025
Peter Soparkar CHIEF OPERATING OFFICER
BUY
Grant, award, or other acquisition
Direct
13,125 +23.76%
-
Jul 30 2024
Braden Michael Leonard
BUY
Open market or private purchase
Indirect
85,800 +3.65%
$600,600 $7.15 P/Share
Jul 18 2024
Braden Michael Leonard
BUY
Open market or private purchase
Indirect
80,718 +3.57%
$726,462 $9.11 P/Share
Jul 17 2024
Braden Michael Leonard
BUY
Open market or private purchase
Indirect
135,546 +6.06%
$948,822 $7.75 P/Share
Feb 07 2024
Lupher, Jr. Mark L.
BUY
Open market or private purchase
Direct
130,000 +50.0%
$130,000 $1.35 P/Share
Feb 07 2024
James Paul Scopa
BUY
Open market or private purchase
Direct
100,000 +50.0%
$100,000 $1.35 P/Share
Sep 15 2023
Setareh Seyedkazemi CHIEF DEVELOPMENT OFFICER
SELL
Open market or private sale
Direct
6,201 -5.77%
$6,201 $1.54 P/Share
Jun 07 2023
Linda M Rubinstein CHIEF FINANCIAL OFFICER
BUY
Open market or private purchase
Direct
100,000 +50.0%
$100,000 $1.45 P/Share
Mar 15 2023
Laurent Fischer CEO, PRESIDENT AND DIRECTOR
SELL
Open market or private sale
Direct
41,239 -5.62%
$0 $0.78 P/Share
Mar 15 2023
Peter Soparkar CHIEF OPERATING OFFICER
SELL
Open market or private sale
Direct
13,360 -4.78%
$0 $0.78 P/Share
Mar 15 2023
Brigit Riley Chief Scientific Officer
SELL
Open market or private sale
Direct
7,299 -5.85%
$0 $0.78 P/Share
Sep 19 2022
Richard Beckman Chief Medical Officer
SELL
Open market or private sale
Direct
4,272 -9.86%
$4,272 $1.07 P/Share
Sep 19 2022
Setareh Seyedkazemi CHIEF DEVELOPMENT OFFICER
SELL
Open market or private sale
Direct
6,058 -11.23%
$6,058 $1.07 P/Share
Sep 19 2022
Peter Soparkar CHIEF OPERATING OFFICER
SELL
Open market or private sale
Direct
13,305 -4.64%
$13,305 $1.07 P/Share
Sep 19 2022
Brigit Riley Chief Scientific Officer
SELL
Open market or private sale
Direct
7,266 -5.77%
$7,266 $1.07 P/Share
Sep 19 2022
Laurent Fischer CEO, PRESIDENT AND DIRECTOR
SELL
Open market or private sale
Direct
41,082 -5.35%
$41,082 $1.07 P/Share
Sep 14 2022
Richard Beckman Chief Medical Officer
BUY
Grant, award, or other acquisition
Direct
25,000 +41.67%
-
Sep 14 2022
Setareh Seyedkazemi CHIEF DEVELOPMENT OFFICER
BUY
Grant, award, or other acquisition
Direct
33,333 +38.2%
-
May 23 2022
Setareh Seyedkazemi CHIEF DEVELOPMENT OFFICER
BUY
Open market or private purchase
Direct
20,000 +49.26%
$0 $0.84 P/Share
May 17 2022
Richard Beckman Chief Medical Officer
BUY
Open market or private purchase
Direct
10,000 +50.0%
$0 $0.82 P/Share
May 17 2022
Rupert D'Souza Chief Financial Officer
BUY
Open market or private purchase
Direct
10,000 +32.41%
$0 $0.83 P/Share
May 16 2022
Dawn Svoronos
BUY
Open market or private purchase
Direct
30,000 +37.5%
$0 $0.85 P/Share
May 13 2022
Rupert D'Souza Chief Financial Officer
BUY
Open market or private purchase
Direct
10,000 +47.96%
$0 $0.86 P/Share
Apr 20 2022
Laurent Fischer CEO, PRESIDENT AND DIRECTOR
BUY
Open market or private purchase
Direct
25,000 +3.17%
$25,000 $1.11 P/Share
Apr 19 2022
Peter Soparkar CHIEF OPERATING OFFICER
BUY
Open market or private purchase
Direct
21,925 +3.63%
$21,925 $1.14 P/Share
Dec 09 2021
Laurent Fischer CEO, PRESIDENT AND DIRECTOR
BUY
Open market or private purchase
Direct
14,323 +1.91%
$14,323 $1.85 P/Share
Dec 08 2021
Peter Soparkar CHIEF OPERATING OFFICER
BUY
Open market or private purchase
Direct
25,000 +8.81%
$25,000 $1.91 P/Share
Dec 08 2021
Laurent Fischer CEO, PRESIDENT AND DIRECTOR
BUY
Open market or private purchase
Direct
10,677 +1.46%
$10,677 $1.79 P/Share
Nov 15 2021
James Paul Scopa
SELL
Open market or private sale
Indirect
50,000 -93.75%
$100,000 $2.18 P/Share
Sep 30 2021
Julie Clark Chief Medical Officer
SELL
Open market or private sale
Direct
4,766 -2.81%
$9,532 $2.17 P/Share
Aug 06 2021
Laurent Fischer CEO, PRESIDENT AND DIRECTOR
BUY
Grant, award, or other acquisition
Direct
680,000 +49.05%
-
Aug 06 2021
Peter Soparkar CHIEF OPERATING OFFICER
BUY
Grant, award, or other acquisition
Direct
220,000 +48.81%
-
Aug 06 2021
Angela Thedinga Chief Technology Officer
BUY
Grant, award, or other acquisition
Direct
150,000 +50.0%
-
Aug 06 2021
Julie Clark Chief Medical Officer
BUY
Grant, award, or other acquisition
Direct
120,000 +41.45%
-
Mar 31 2021
Dawn Svoronos
BUY
Open market or private purchase
Direct
20,000 +50.0%
$200,000 $10.02 P/Share
Mar 24 2021
Patrick Machado
BUY
Open market or private purchase
Direct
10,000 +10.19%
$90,000 $9.92 P/Share

Track Institutional and Insider Activities on ADVM

Follow Adverum Biotechnologies, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ADVM shares.

Notify only if
Any

Insider Trading

Get notified when an Adverum Biotechnologies, Inc. insider buys or sells ADVM shares.

Notify only if
Any
Any
P - Open market or private purchase×
S - Open market or private sale×
V - Transaction voluntarily reported earlier than required×
A - Grant, award, or other acquisition×
D - Sale (or disposition) back to the issuer×
F - Payment of exercise price or tax liability×
I - Discretionary transaction×
M - Exercise of conversion of derivative security×
C - Conversion of derivative security×
E - Expiration of short derivative position×
H - Expiration (or cancellation) of long derivative position with value received×
O - Exercise of out-of-the-money derivative securities×
X - Exercise of in-the-money or at-the-money derivatives securities×
G - Bona fide gift×
L - Small Acquisition×
W - Acquisition or disposition by will or laws×
Z - Deposit into or withdrawal from voting trust×
J - Other acquisition or disposition×
K - Transaction in equity swap or similar instrument×
U - Disposition due to a tender of shares in a change of control transaction×
20 item(s) selected

News

Receive news related to Adverum Biotechnologies, Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on ADVM